Focus Universal (FCUV) vs Niki BioSolutions (NIKI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Niki BioSolutions is the larger company by market cap ($4.9 million vs $3.9 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FCUV | NIKI |
|---|---|---|
| Share price | $3.94 | $1.57 |
| Market cap | $3.87M | $4.90M |
| 1-day change | -8.37% | -6.55% |
| YTD return | — | -85.19% |
| 1-year return | — | -87.92% |
| 5-year return | — | -99.18% |
| EPS (TTM) | $-14.92 | $-2.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $255.02K | — |
| Revenue growth (YoY) | -35.95% | — |
| Net income (latest FY) | $-4.79M | $-1.36M |
| Gross margin | -13.82% | — |
| Operating margin | -1918.75% | — |
| Net margin | -1877.39% | — |
| 52-week high | $158.40 | $14.40 |
| 52-week low | $1.79 | $1.42 |
| Distance from 52-week high | -97.51% | -89.10% |
| Average volume | 2.04M | 97.67K |
| Shares outstanding | 982.01K | 2.94M |
| Employees | 37 | 1 |
| Sector | Industrials | Industrials |
| Industry | Industrial Machinery/Components | Industrial Machinery/Components |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Focus Universal
FCUV stock →Focus Universal Inc. develops and commercializes universal smart technologies and instruments in the United States.
Industrials · Industrial Machinery/Components · 37 employees
About Niki BioSolutions
NIKI stock →Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa.
Industrials · Industrial Machinery/Components · 1 employees
FCUV vs NIKI FAQ
Which is bigger, Focus Universal or Niki BioSolutions?
Niki BioSolutions (NIKI) is larger, with a market capitalization of $4.90M compared with $3.87M for Focus Universal (FCUV).
Are Focus Universal and Niki BioSolutions in the same industry?
Yes. Both are classified in the Industrial Machinery/Components industry within the Industrials sector.